Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women

被引:18
作者
Bartlett, Thomas E. [1 ]
Evans, Iona [2 ]
Jones, Allison [2 ]
Barrett, James E. [2 ,3 ,4 ]
Haran, Shaun [2 ]
Reisel, Daniel [2 ]
Papaikonomou, Kiriaki [5 ,6 ]
Jones, Louise [7 ]
Herzog, Chiara [3 ,4 ]
Pashayan, Nora [8 ]
Simoes, Bruno M. [9 ]
Clarke, Robert B. [9 ]
Evans, D. Gareth [10 ,11 ]
Ghezelayagh, Talayeh S. [12 ,13 ]
Ponandai-Srinivasan, Sakthivignesh [5 ,6 ]
Boggavarapu, Nageswara R. [5 ,6 ]
Lalitkumar, Parameswaran G. [5 ,6 ]
Howell, Sacha J. [9 ,14 ]
Risques, Rosa Ana
Radestad, Angelique Floter [5 ,6 ]
Dubeau, Louis [15 ]
Gemzell-Danielsson, Kristina [5 ,6 ]
Widschwendter, Martin [2 ,3 ,4 ,5 ,6 ]
机构
[1] UCL, Dept Stat Sci, London WC1E 7HB, England
[2] UCL, UCL EGA Inst Womens Hlth, Dept Womens Canc, 74 Huntley St, London WC1E 6AU, England
[3] Univ Innsbruck, European Translat Oncol Prevent & Screening EUTOP, A-6060 Hall In Tirol, Austria
[4] Univ Innsbruck, Res Inst Biomed Aging Res, A-6020 Innsbruck, Austria
[5] Karolinska Inst, Div Obstet & Gynecol, Dept Womens & Childrens Hlth, Stockholm, Sweden
[6] Karolinska Univ Hosp, Stockholm, Sweden
[7] Queen Mary Univ London, Barts Canc Inst, Ctr Tumour Biol Dept, London, England
[8] UCL, Dept Appl Hlth Res, 1-19 Torrington Pl, London WC1E 7HB, England
[9] Univ Manchester, Div Canc Sci, Manchester Breast Ctr, Breast Biol Grp,Fac Biol, Manchester, Lancs, England
[10] Univ Manchester, St Marys Hosp, Manchester, Lancs, England
[11] Univ Hosp South Manchester, Manchester, Lancs, England
[12] Univ Washington, Dept Lab Med & Pathol, Seattle, WA 98195 USA
[13] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA
[14] Christie NHS Fdn Trust, Dept Med Oncol, Manchester, Lancs, England
[15] Univ Southern Calif, USC Norris Comprehens Canc Ctr, Keck Sch Med, Dept Pathol, Los Angeles, CA 90007 USA
基金
瑞典研究理事会;
关键词
Breast cancer; Prevention; Antiprogestins; BRCA1; Intermediate surrogate marker; Epigenetics; DNA methylation; CANCER-RISK; RECEPTOR MODULATORS; DNA METHYLATION; RANK LIGAND; BRCA1; MUTATIONS; OVARIAN; CELLS; PREVENTION; HORMONE;
D O I
10.1186/s13073-022-01063-5
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: Breast cancer is a leading cause of death in premenopausal women. Progesterone drives expansion of luminal progenitor cells, leading to the development of poor-prognostic breast cancers. However, it is not known if antagonising progesterone can prevent breast cancers in humans. We suggest that targeting progesterone signalling could be a means of reducing features which are known to promote breast cancer formation. Methods: In healthy premenopausal women with and without a BRCA mutation we studied (i) estrogen and progesterone levels in saliva over an entire menstrual cycle (n = 20); (ii) cancer-free normal breast-tissue from a control population who had no family or personal history of breast cancer and equivalently from BRCA1/2 mutation carriers (n = 28); triple negative breast cancer (TNBC) biopsies and healthy breast tissue taken from sites surrounding the TNBC in the same individuals (n = 14); and biopsies of ER+ve/PR+ve stage T1-T2 cancers and healthy breast tissue taken from sites surrounding the cancer in the same individuals (n = 31); and (iii) DNA methylation and DNA mutations in normal breast tissue (before and after treatment) from clinical trials that assessed the potential preventative effects of vitamins and antiprogestins (mifepristone and ulipristal acetate; n = 44). Results: Daily levels of progesterone were higher throughout the menstrual cycle of BRCA1/2 mutation carriers, raising the prospect of targeting progesterone signalling as a means of cancer risk reduction in this population. Furthermore, breast field cancerization DNA methylation signatures reflective of (i) the mitotic age of normal breast epithelium and (ii) the proportion of luminal progenitor cells were increased in breast cancers, indicating that luminal progenitor cells with elevated replicative age are more prone to malignant transformation. The progesterone receptor antagonist mifepristone reduced both the mitotic age and the proportion of luminal progenitor cells in normal breast tissue of all control women and in 64% of BRCA1/2 mutation carriers. These findings were validated by an alternate progesterone receptor antagonist, ulipristal acetate, which yielded similar results. Importantly, mifepristone reduced both the TP53 mutation frequency as well as the number of TP53 mutations in mitotic-age-responders. Conclusions: These data support the potential usage of antiprogestins for primary prevention of poor-prognostic breast cancers.
引用
收藏
页数:18
相关论文
共 71 条
[1]   Inference of tissue relative proportions of the breast epithelial cell types luminal progenitor, basal, and luminal mature [J].
Bartlett, Thomas E. ;
Jia, Peiwen ;
Chandna, Swati ;
Roy, Sandipan .
SCIENTIFIC REPORTS, 2021, 11 (01)
[2]   Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease [J].
Bianchini, Giampaolo ;
Balko, Justin M. ;
Mayer, Ingrid A. ;
Sanders, Melinda E. ;
Gianni, Luca .
NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (11) :674-690
[3]  
Bogavarappu NR., 2022, TARGETING PROGESTERO
[4]   Selective estrogen receptor modulators and their effects on hot flashes: a dilemma [J].
Bouchard, Celine .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2011, 18 (05) :477-479
[5]   Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety [J].
Bouchard, Philippe ;
Chabbert-Buffet, Nathalie ;
Fauser, Bart C. J. M. .
FERTILITY AND STERILITY, 2011, 96 (05) :1175-1189
[6]   Progesterone signalling in breast cancer: a neglected hormone coming into the limelight [J].
Brisken, Cathrin .
NATURE REVIEWS CANCER, 2013, 13 (06) :385-396
[7]   Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials [J].
Chlebowski, Rowan T. ;
Anderson, Garnet L. ;
Aragaki, Aaron K. ;
Manson, JoAnn E. ;
Stefanick, Marcia L. ;
Pan, Kathy ;
Barrington, Wendy ;
Kuller, Lewis H. ;
Simon, Michael S. ;
Lane, Dorothy ;
Johnson, Karen C. ;
Rohan, Thomas E. ;
Gass, Margery L. S. ;
Cauley, Jane A. ;
Paskett, Electra D. ;
Sattari, Maryam ;
Prentice, Ross L. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (04) :369-380
[8]   Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells [J].
Chodankar, R ;
Kwang, S ;
Sangiorgi, F ;
Hong, H ;
Yen, HY ;
Deng, CX ;
Pike, MC ;
Shuler, CF ;
Maxson, R ;
Dubeau, L .
CURRENT BIOLOGY, 2005, 15 (06) :561-565
[9]   Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis [J].
Cummings, Steven R. ;
San Martin, Javier ;
McClung, Michael R. ;
Siris, Ethel S. ;
Eastell, Richard ;
Reid, Ian R. ;
Delmas, Pierre ;
Zoog, Holly B. ;
Austin, Matt ;
Wang, Andrea ;
Kutilek, Stepan ;
Adami, Silvano ;
Zanchetta, Jose ;
Libanati, Cesar ;
Siddhanti, Suresh ;
Christiansen, Claus .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (08) :756-765
[10]   Tamoxifen-Induced Reduction in Mammographic Density and Breast Cancer Risk Reduction: A Nested Case-Control Study [J].
Cuzick, Jack ;
Warwick, Jane ;
Pinney, Elizabeth ;
Duffy, Stephen W. ;
Cawthorn, Simon ;
Howell, Anthony ;
Forbes, John F. ;
Warren, Ruth M. L. .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (09) :744-752